حدد سهمًا أو عملة مشفرة في شريط البحث للحصول على ملخص
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS
GENILGen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV for the development of molecule SUL-238 as a treatment for Alzheimer's disease and other neurodegenerative diseases. The company was incorporated in 1997 and is headquartered in Çankaya, Turkey. Address: Mustafa Kemal District 2119, Çankaya, Turkey, 06520
Analytics
سعر الهدف في وول ستريت
4 331.95 TRYنسبة السعر إلى الأرباح
45.26العائد الربحي
0.74 %السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
الشخصيات الرئيسية GENIL
تحليلات الأرباح GENIL
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–نمو الأرباح على مدى 5 سنوات
–النمو المستمر
–معدل الدفع 5 سنوات في المتوسط
21.00 %تاريخ الأرباح GENIL
تقييم الأسهم GENIL
المالية GENIL
نتائج | 2019 | ديناميات |